Ivoximab and temozolomide for recurring brain tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs—ivoximab (a new immunotherapy) and temozolomide (chemotherapy)—to treat gliomas (brain tumors) that have come back or stopped responding to prior treatment. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a glioma (brain tumor) that has come back or is no longer responding to previous treatment, confirmed by biopsy and imaging
- You are in good overall health with an ECOG score of 0–1 (able to do most daily activities)
- You are expected to live at least 6 months
- Your organ function (liver, kidney, blood counts) meets minimum requirements
- You have not had immunotherapy drugs (anti-PD-1, anti-PD-L1, or similar) before
- You can swallow pills and do not have bowel obstruction
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests a new drug called ivonescimab for people whose glioblastoma has come back after standard treatment. The goal is to see if this drug can help shrink the tumor or slow its growth.
This trial tests a combination of two oral medications (vebreltinib and temozolomide) after surgery for a specific type of brain cancer called glioblastoma. The goal is to see if this combination can help stop the cancer from growing back.
This study tests a combination of two oral medications, niraparib and temozolomide, for people whose brain tumor (glioblastoma or a related glioma) has come back after standard treatment. The goal is to see if this combination can slow or stop the tumor from growing.
Hear when a new Relapsed/Refractory Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.